R&D Views & Analysis | pharmaphorum

Views & Analysis

JP Morgan

JPM2023: Breakthroughs await, but so do roadblocks

Editor-in-chief Jonah Comstock lays out a few of the most potent threads he heard in the conference centres, hotel rooms, and rain-soaked Lyfts of San Francisco.

Digital

The importance of AI literacy in life sciences

The promise and value of artificial intelligence (AI) in life sciences are somewhat obscured by the over-generalisation of this technology.

Digital

AI and the Big Data paradigm – big ambitions in novel drug d...

Over the past few decades, data generation has veritably exploded.

R&D

JP Morgan 2023 – Day 2

Tuesday brings the on-site part of Fierce’s JPM event as well as day 2 of the Informa Biotech Showcase.

R&D

Connected customer data: a golden opportunity for pharma mar...

Data is transforming life sciences, but many organisations are not using its full potential.

Market Access

Nine for 2023, part one: a reflection on inflection

The Roman god Janus, as we are frequently reminded in January, was two faced and able to look forward to the coming year and backward to reflect on the past one.